Acadia's New CEO Tightens Operations: From Bed Building to Bed Filling
Acadia Healthcare's first quarter 2026 report isn't just about numbers – it's a statement of strategic intent. Newly returned CEO Debbie Osteen is reorienting the company from a heavy capital investment phase to one focused on operational discipline and filling the beds it already has. The results were decent, but the real signal is in the direction of change.
For 2026, our primary focus is operational execution and deriving more value from our facilities and recent bed additions.
A Pivot from Building to Operating
Osteen's early moves have been decisive. She's restructured the acute service line, reduced corporate headcount, and introduced new leadership. As she put it: “Our first quarter financial and operating results marked a good start to 2026.” — Debra Osteen, Chief Executive Officer · 2026-04-30 This is a clear departure from the previous stance of aggressive expansion. The company has historically added thousands of beds, but now it's slowing that pace. In fact, ramping facility performance is now a key metric, with the company saying the 2023-2025 cohort overachieved in Q1.
The operational changes include creating a new operating group for acute facilities to focus on joint venture hospitals and recently opened facilities. Osteen noted, “We have specific plans, as I mentioned, and they really focus on continued ramping of occupancy into the facility.” — Debra Osteen, Chief Executive Officer · 2026-04-30 This suggests a hands-on approach to turning around underperforming specialty facility locations and ensuring new acute beds reach maturity faster.
Financials: A Beat, But Bad Debts Bite
The headline numbers looked good: revenue grew 7.6% to $828.8M, adjusted EBITDA of $144.2M came in $7.2M above the high end of guidance. But the quarter also exposed a persistent problem: bad debts and denials are running hotter than expected. Todd Young, CFO, said: “We thought bad debts and denials have started to stabilize in Q4, but then they continue to get a little bit worse in Q1 than what we had previously expected.” — Todd Young, Chief Financial Officer · 2026-04-30 This is a recurring theme – the company has been fighting payer friction for over a year. The prior management had flagged it, and now Osteen is bringing in consultants and using AI to improve documentation and appeals. The bad debt pressure is now embedded in the full-year guidance, but the company still raised its adjusted EBITDA and EPS ranges, signaling confidence in its ability to offset some of this headwind through cost cuts.
Importantly, management sees the bad debt trend as a fixable operational challenge, not a structural one. They've re-engaged a former executive, Larry Hard, to lead revenue cycle improvements. This aligns with the broader strategic shift toward efficiency.
Capital Discipline and the Ramp
The most tangible change is in capital allocation. CapEx has been slashed dramatically – from a peak of $184M in Q2 2025 to just $77M in Q1 2026. Capital expenditure is now projected at $255-280M for the full year, down by over $300M from the prior year. This isn't just belt-tightening; it's a conscious pivot. As Todd Young said on the prior call, “We will continue to evaluate opportunities in markets that have high demand and meet our threshold for bed adds, understanding that the cost of construction has increased a lot over the last few years.” — Todd Young, Chief Financial Officer · 2026-02-25 The company is now prioritizing bed expansions at existing facilities over new builds, and the JV facilities being opened this year are already partially funded.
The strategy is to let the existing portfolio generate cash and drive organic growth. The company expects start-up losses to peak in Q2 then decline, and the new facilities are already performing ahead of expectations. With 400-600 net bed additions planned for 2026, the focus is on occupying them efficiently. As Osteen put it, the goal is to eliminate barriers to access and improve referral relationships.
This shift hasn't gone unnoticed by the market – the stock is still down hugely from its 2022 peak, but the recent trend (up 17 weeks before a pullback) suggests investors are cautiously optimistic about the execution story.